Clinical Trial Update: Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14 [Phase 3]

View source ↗

Summary

A completed Phase 3 study comparing two brands of modified-release oral formulations for safety and efficacy in children aged 6 to 14 with ADHD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Brand A
• Brand B

Snippet

Sponsor: Novartis | Conditions: ADHD | Phase 3 | Status: COMPLETED